StemCell Therapy

Global Medical Foods Market: Overview

One of the key factors boosting the growth of the global medical foods market is the rising awareness among the people regarding medical foods. The rising focus of the regulatory bodies on the manufacturing and labelling of medical foods will also be a key factor fuelling the growth of the medical foods market. In addition to this, the high focus by manufacturers on developing disease-specific formulas effective patients nutrition or diet care are also anticipated to result in the growth of the global medical foods market.

The report also enlists various factors which are anticipated to pose a challenge for the growth of the market. The current trends in the market and those that are anticipated to shape the future of the market have been discussed in detail in the report.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2558

By product, the medical food market is segmented into powder, pill, and others. Of these the powder segment has held a key share in the market as many medical food products are manufactured in powdered form and consumed in a semi solid or liquid form. By application, the global medical foods market is segmented into depression, diabetic neuropathy, ADHD, Alzheimers disease, and nutritional deficiency. Of these, diabetic neuropathy has been accounting for key shares within the market. The risk of neuropathy is boosted with age, diet changes, and unhealthy lifestyle.

In the years to come, it is anticipated that the nutritional deficiencies segment will develop a strong CAGR, as patients being treated for ADHD, autoimmune diseases, and cancer are likely to have high nutritional requirements, which is subsequently anticipated to boost the demand for medical foods.

Global Medical Foods Market: Snapshot

The global medical foods market has become increasingly important in the healthcare sector in recent years due to the rising awareness about its importance in complementing the treatment. Medical food comprises diets designed specifically to overcome the nutritional deficiencies caused by some diseases or to fulfill the specific dietary needs in the management of some diseases. The global medical foods market is likely to receive steady support from the healthcare sector in the coming years due to the rising prevalence of diseases such as Alzheimers among the elderly and ADHD among children, as these diseases are among the prime diseases that necessitate specific diet plans.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2558

Global Medical Foods Market: Key Trends

The rising geriatric population is a major driver for the global medical foods market. Old people are more likely to develop nutritional disorders as well as to fall prey to other diseases that affect their ability to absorb nutrients from their diet. Nutrition deficiency disorders are also more common among the geriatric demographic than in other patient classes, leading to the geriatric population becoming a key consumer segment for the global medical foods market.

The increasing prevalence of diabetes across the world is another key driver for the global medical foods market. Diabetic neuropathy is the leading application of the global medical foods market and is likely to retain dominance in the coming years. Diabetic neuropathy is becoming common among diabetic patients due to their often unhealthy lifestyles, with close to three-quarters of all diabetes likely to also suffer from some form of neuropathy. This is a key driver for the global medical food market, as the rising prevalence of diabetes in emerging regions has, in conjunction with the rising investment in the healthcare sector, created a conducive environment for growth of the market.

The rising prevalence of ADHD among children is also likely to remain a key driver for the global medical foods market. The growing prevalence of the disease has led to intensive research into its causation and treatment. The role of nutrition in the management of psychological problems such as ADHD has thus come under the scanner. On the opposite end of the spectrum, the rising prevalence of neurodegenerative conditions among the geriatric population is also likely to remain a key driver for the global medical foods market in the coming years.

Global Medical Foods Market: Market Potential

The global medical foods market is likely to witness a steady shift towards pills and away from powders. While powders can be easily mixed with various types of food, many patients dont enjoy their taste. This has led to pills becoming a preferred mode of delivery for many, and are thus likely to rise in demand in the global medical foods market in the coming years.

Apart from leading diseases such as diabetic neuropathy and Alzheimers, other diseases such as phenylketonuria (PKU) are also likely to come under the ambit of the medical food market in the coming years. In April 2017, PKU Sphere, a new medical food for patients of PKU was launched. PKU Sphere is claimed to contain a balanced mix of amino acids and glycomacropeptide, a protein essential for patients of PKU, who cant digest phenylalanine and have to fulfill their protein requirements in alternate ways.

Global Medical Foods Market: Geographical Dynamics

North America is likely to remain the leading regional contributor to the global medical foods market in the coming years due to the ready availability of advanced healthcare technology and a solid database regarding the dietary needs of patients suffering from various diseases. The rising prevalence of diabetes in North America, due primarily to the unhealthy lifestyle practiced by citizens in developed countries such as the U.S., is also likely to be crucial for the medical foods market in North America in the coming years.

Global Medical Foods Market: Competitive Dynamics

The leading players in the global medical foods market include Abbott, Fresenius Kabi AG, Targeted Medical Pharma Inc., Danone, and Primus Pharmaceuticals Inc. The steady support to development of sophisticated disease-specific formulas is likely to benefit the medical foods market in the coming years.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/medical-foods-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Excerpt from:
Medical Foods Market Analysis Trends and Dynamic Demand by Forecast 2017 to 2025 - Jewish Life News

The Global Neuropathic Pain Drug Market is expected to grow from USD 7,598.48 Million in 2018 to USD 13,938.27 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 9.05%.

The report contains a wide-view explaining Neuropathic Pain Drug Market on the global and regional basis. Global Neuropathic Pain Drug market report is a definitive source of information and provides latest market research intelligence, changing consumer trends with actionable insights on emerging players, products, and technologies. Our analysts possess statistical data to provide insights on statistical report including the factors responsible for driving and hindering the growth of the market along with the impact theyll have on the demand over the coming years.

The study is a combined effort of primary as well as secondary research. The report gives insights on the key factors concerned with generating and limiting Neuropathic Pain Drug industry growth. Additionally, the report also studies competitive developments, such as mergers and acquisitions, new partnerships, new contracts, and new product developments in the global Neuropathic Pain Drug market. The past trends and future prospects included in this report makes it highly comprehensible for the analysis of the market. Moreover, the latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the Neuropathic Pain Drug market have also been included in the study.

Neuropathic Pain Drug industry competition by top manufacturers/ Key player Profiled:Bristol-Myers Squibb and Company, Eli Lily and Company, GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Pfizer Inc., Baxter Healthcare Corporation, Biogen Idec Inc., Depomed Inc., and Sanofi S.A.. On the basis of Type, the Global Neuropathic Pain Drug Market is studied across Phantom Limb Pain, Post Herpetic Neuralgia, Post-traumatic Neuropathy, and Trigeminal Neuralgia.

On the basis of Treatment, the Global Neuropathic Pain Drug Market is studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type.

On the basis of Indication, the Global Neuropathic Pain Drug Market is studied across Diabetic Neuropathy and Spinal Stenosis.

On the basis of Diagnosis, the Global Neuropathic Pain Drug Market is studied across Blood Tests and Imaging Physical Examination.

On the basis of Distribution, the Global Neuropathic Pain Drug Market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores.

On the basis of End User, the Global Neuropathic Pain Drug Market is studied across Clinics and Hospitals.

Get a Sample PDF of report @ https://www.regalintelligence.com/request-sample/24893

Scope of the Neuropathic Pain Drug Market Report:

APAC is expected to dominate the global Neuropathic Pain Drug market during the forecast period. The worldwide market for Neuropathic Pain Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2025, from xx million US$ in 2019, according to the study. This report focuses on the Neuropathic Pain Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa.

The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rateofNeuropathic Pain Drugmarket in 2025is also explained. Additionally, type wise and application wise consumptiontables andfiguresof Neuropathic Pain Drugmarketare also given.

Objective of Studies:

Report on Global Neuropathic Pain Drug Industry 2019 mainly covers 10 Section in Table as follows:-

Look into Table of Content of Neuropathic Pain Drug Industry Report @ https://www.regalintelligence.com/request-toc/24893

Contact Us:Regal Intelligencewww.regalintelligence.comsales@regalintelligence.comPh no: +1 231 930 2779 (U.S.)

Follow Us:https://in.linkedin.com/company/regal-intelligencehttps://www.facebook.com/regalintelligence/https://twitter.com/RI_insights

Continued here:
The Global Neuropathic Pain Drug Market is expected to grow from USD 7,598.48 Million in 2018 to USD 13,938.27 Million by the end of 2025 at a...

A team of researchers from the NUS Yong Loo Lin School of Medicine has identified a novel protein that would prevent the development of neuropathy in cancer patients who receive chemotherapy.

Chemotherapy is one of the most commonly recommended treatments for many forms of cancer. One major side effect, however, is peripheral neuropathy, or the damage or dysfunction of one or more nerves that typically results in numbness, tingling, muscle weakness and pain in the affected area. It frequently starts in a patient's hands and feet, though other regions and parts of the body can also be affected.

At the moment, there is no way to prevent or treat neuropathy caused by chemotherapy drugs. The only option is to limit or discontinue the chemotherapy treatment. As a result, many patients are not able to tolerate chemotherapy well.

In a recent study published by theJournal of Biological Chemistry, a team of researchers jointly led by Assistant Professor Raymond Deron Herr and Assistant Professor Raghav Sundar from the NUS Yong Loo Lin School of Medicine set out to examine whether S1P2, a receptor protein that resides on the surface of cells in the nervous system, is a potential target in the treatment of chemotherapy-induced neuropathy. The team first looked at the effects of platinum-based chemotherapy drugs, such as cisplatin, on the regulation of S1P2 and found that chemotherapy alters S1P2 activity. The team further demonstrated that the activation of S1P2 with a drug-like compound, can protect the nerve cells from damage and pain. This is in contrast to the accumulation of free radicals in nerves, leading to nerve degeneration when the receptor is removed. The team concluded that it is possible to block both the nerve injury and the pain when S1P2 is activated with a drug while administering cisplatin.

There are three major classes of drugs that cause neuropathy: platinum compounds (cisplatin and oxaliplatin), taxanes (paclitaxel), and a targeted medication known as bortezomib.

"While the study focused on the effects of cisplatin, based on what we know about the molecular processes, it is likely that an S1P2 drug will work in all cases of chemotherapy-induced neuropathy. Furthermore, it is possible that such a drug could treat many other forms of neuropathy, such as those caused by nerve injury, autoimmune disease, or diabetes," said Dr Herr.

"Neuropathy or numbness from chemotherapy is a common and debilitating side-effect faced by patients, with few proven treatments. Our study provides a deeper understanding of the biology of this condition, allowing potential treatments to reduce chemotherapy-induced neuropathy to be developed. We are currently exploring new drug molecules that would allow the activation of S1P2 in a more effective and stable manner," added Dr Sundar, who is also a Consultant with the Department of Haematology-Oncology at the National University Cancer Institute, Singapore (NCIS) and the National University Hospital.

Reference: Wang, et al. (2020) Activation of sphingosine 1-phosphate receptor 2 attenuates chemotherapy-induced neuropathy. Journal of Biological Chemistry DOI:10.1074/jbc.RA119.011699

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Continued here:
Protein Prevents Neuropathy From Chemotherapy - Technology Networks

High levels of glucose in the blood can damage the peripheral nerves in your body, causing decreased sensation in the feet and hands as well as problems to the urinary tract, digestive system, and heart. With over 60 per cent of diabetics eventually developing peripheral neuropathy, it is one of the main secondary complications they face. Mild to moderate symptoms include pain, numbness and tingling sensation in the feet and legs. Fortunately, diabetic neuropathy can be prevented if strict control is maintained on blood sugar levels on a daily basis. Lifestyle changes and complementary therapies can help achieve this effectively. Three of the most commonly practiced alternative therapies to help prevent diabetic neuropathy are naturopathy, yoga and acupuncture.

Acupuncture

Acupuncture uses the science of inserting long, fine needles at various points in the body to stimulate the sensory receptors and stimulate them. A study published in the Journal of Thai Traditional and Alternative Medicine found that acupuncture drastically improves the positive effects of diabetes medication and alleviates the symptoms of diabetic neuropathy. Once they started the acupuncture regimen, the success rate of the symptom score went up from 8 percent to 90 per cent. The neuropathic disability score also went up from 37.45 to 90 once acupuncture was introduced into the treatment regimen.

Naturopathic and yogic interventions to improve diabetic neuropathy

Diet and exercise: The best defense against progressive damage from diabetic neuropathy is to manage the disease itself. Keep your blood sugar levels in check by eating healthy. Ensure that your diet includes a lot of fiber rich foods and whole grains, and very little saturated and trans fats. Structured physical interventions also play an important role in keeping blood sugar levels in check. Make sure you get at least 30 minutes of aerobic exercise every day. Meditation and deep breathing can help you manage chronic stress.

Supplements: Winter ginseng is very effective at keeping the blood sugar in control and managing the symptoms of peripheral neuropathy. Not only does it help increase the level of serum insulin, it also improves the insulin sensitivity of muscle cells as well as the bodys glucose tolerance, thereby easing the severity of diabetic neuropathy.

Yoga poses for the management of neuropathy

Yoga helps improve blood flow to the extremities, improves the bodys glucose tolerance and insulin sensitivity.

Exercise for feet and hands: Sit down in padmasana and extend your arms fully in front of your chest. This pose will help stretch both fingers and toes. It will help improve blood flow to the periphery and strengthen your nerves. If you can do it for a few minutes every day, you will start to experience relief.

Poses for diabetic neuropathy: If the condition is not severe, then traditional hatha yoga poses like trikonasana, ustrasana and dhanurasana will do. If the neuropathy is more advanced, it needs gentler practice under the guidance of a trained instructor. However, you can still benefit from gentle twist exercises, meditation and closely supervised backbends.

More:
Yoga to acupuncture: Alternative therapies to prevent diabetic neuropathy - Business Standard

The report titled Global Chemotherapy Induced Peripheral Neuropathy Treatment Market is one of the most comprehensive and important additions to Reportspedia archive of market research diaries. It offers thorough research and analysis of major aspects including market size, market growth rate, market profitability, industry cost structure, distribution channel, market trends, and key success factors of the market.

The report includes SWOT and PESTLE analyses to provide a deeper understanding of the industry. All of the foremost companies included in the report are profiled based on gross margin, market share, forthcoming strategies, recent expansions, target customer demographics, products and applications, and other critical factors. The report also offers regional analysis of the Chemotherapy Induced Peripheral Neuropathy Treatment market with high focus on market growth, growth rate, and growth potential.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market is valued at USD XX million in 2019 and is projected to reach US$ XX million till 2025, rising at a CAGR of 6.2% during the period 2019 to 2025.

Major Players involved in the Global Chemotherapy Induced Peripheral Neuropathy Treatment Market:

Aptinyx Inc, Sova Pharmaceuticals Inc, MAKScientific LLC, Asahi Kasei Pharma Corp, PledPharma, Regenacy Pharmaceuticals, Immune Pharmaceuticals Inc, Nemus Bioscience Inc, Metys Pharmaceuticals AG, DermaXon LLC, WinSanTor, Kineta Inc, Solasia Pharma K.K., Apexian Pharma, Krenitsky Pharmaceuticals Inc, PeriphaGen,

Get Free PDF Sample Report(Including Full TOC, List of Tables & Figures, Chart):https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368#request_sample

Market Competition

The vendor landscape and competitive scenarios of the global Chemotherapy Induced Peripheral Neuropathy Treatment industry are broadly analyzed to help market players gain competitive advantage over their competitors. Market players can use the analysis to prepare themselves for any future challenges well in advance. They will also be able to identify opportunities to attain a position of strength in the global Chemotherapy Induced Peripheral Neuropathy Treatment industry. Furthermore, the examination will help them to successfully channelize their strategies, strengths, and resources to gain maximum advantage.

The Essential Content Covered in the Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry Report:

* Top Key Company Profiles.

* Main Business and Rival Information

* SWOT Analysis and PESTEL Analysis

* Production, Sales, Revenue, Price and Gross Margin

* Market Share and Size

The Chemotherapy Induced Peripheral Neuropathy Treatment Industry segment by regions includes:

Americas (United States, Canada, Mexico, and Brazil), APAC (China, Japan, Korea, Southeast Asia, India, and Australia), Europe (Germany, France, UK, Italy, Russia, and Spain), and Middle East & Africa (Egypt, South Africa, Israel, Turkey, and GCC Countries).

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Product:

By Type Chemotherapy Induced Peripheral Neuropathy Treatment market has been segmented into Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others, etc.

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation by Application:

By Application Chemotherapy Induced Peripheral Neuropathy Treatment has been segmented into Platinum Agents, Taxanes, Vinca Alkaloids, Others, etc.

Inquire Here For Queries Or Report Customization: : https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368#inquiry-before-buying

Key Questions Answered

1) What will be the size and CAGR of the global Chemotherapy Induced Peripheral Neuropathy Treatment market in 2025?

2) Which product will gain the highest request?

3) Which application could show the best development/growth?

4) What will be the competitive landscape in future?

5) Which players will lead the global Chemotherapy Induced Peripheral Neuropathy Treatment market in the coming years?

6) Which region will gain the largest share of the industry?

The report offers comprehensive analysis of the value chain, production, consumption, sales, and opportunities in the global Chemotherapy Induced Peripheral Neuropathy Treatment market. Market players can also use it to get useful endorsements and suggestions from market experts and knowledgeable industry analysts.

Table of Contents

Executive Summary

1 Industry Overview

2 Industry Chain Analysis

3 Manufacturing Technology of Chemotherapy Induced Peripheral Neuropathy Treatment market

4 Major Manufacturers Analysis

5 Global Productions, Revenue and Price Analysis of Chemotherapy Induced Peripheral Neuropathy Treatment market by Regions, Creators, Types and Applications

6 Global and Foremost Regions Capacity, Production, Revenue and Growth Rate of Chemotherapy Induced Peripheral Neuropathy Treatment industry 2015-2019

7 Consumption Volumes, Consumption Value, Import, Export and Trade Price Study of Chemotherapy Induced Peripheral Neuropathy Treatment market by Regions

8 Gross and Gross Margin Examination

9 Marketing Traders or Distributor Examination

10 Worldwide Impacts on Chemotherapy Induced Peripheral Neuropathy Treatment Industry

11 Development Trend Analysis

12 Contact information

13 New Project Investment Feasibility Analysis

14 Conclusion of the Global Chemotherapy Induced Peripheral Neuropathy Treatment Industry 2019 Market Research Report

Continued

Click here to view the full report:https://www.reportspedia.com/report/life-sciences/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2020-by-manufacturers,-regions,-type-and-application,-forecast-to-2025/49368#table_of_contents

Visit link:
Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2020 Research Report by Manufactures, Types, Applications and Forecast to 2025 ...

Qin Yang, Yingxiao Zhang, Qinglian Zeng, Chan Yang, Jiale Shi, Chunlin Zhang, Xia Ni, Zhipeng Du, Ziwei Tang, Jinbo Hu, Xuemei Li, Jiahui Cai, Qifu Li, Qingfeng Cheng

Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Peoples Republic of China

Correspondence: Qingfeng ChengThe First Affiliated Hospital of Chongqing Medical University, No. 1, Youyi Road, Yuanjiagang, Yuzhong District, Chongqing 400042, Peoples Republic of ChinaTel +86-23-89011510Fax +86-23-890115540Email cqf19760516@163.com

Purpose: The present study was designed to determine the relationships between sarcopenia and diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM) and diabetic foot disease (DFD) respectively.Patients and Methods: A total of 1104 patients with T2DM and 257 patients with DFD were included in the study, which was designed as a cross-sectional study. Body composition was assessed using dual-energy X-ray-absorptiometry (DXA). The diagnosis of sarcopenia was based on the Baumgartner criteria. DPN was assessed by Neuropathy symptom score (NSS) and Neuropathy disability score (NDS), and the severity of neuropathy was divided into non-neuropathy symptom (NS), Mild NS, Moderate NS and Severe NS according to NSS. Logistic regression analyses were carried out to determine the relations of sarcopenia and DPN in patients with T2DM and NSS in patients with DFD, respectively.Results: The prevalence of DPN was 80.0% in T2DM patients with sarcopenia and 70.3% in non-sarcopenia patients (P=0.007). Logistic regression analyses showed DPN was one of the independent risk factors for sarcopenia in T2DM patients (OR 1.564 [95% CI: 1.004, 2.435], P=0.048). The prevalence of DPN had no statistical significance in DFD patients with or without sarcopenia. However, the NSS of DFD patients with sarcopenia was higher than that of non-sarcopenia patients. In the multivariate logistic regression analysis, NSS was determined to be associated with sarcopenia in DFD patients (OR 1.387[95% CI: 1.074, 1.789], P=0.012). The appendicular lean mass (ALM) of DFD patients without NS was higher than patients with mild, moderate and severe NS (20.71 2.73 vs 16.57 3.62 vs 17.99 3.54 vs 17.23 3.29 Kg, P=0.028).Conclusion: DPN is an independent risk factor for sarcopenia in patients with T2DM and NSS is also independently correlated with sarcopenia in patients with DFD, with the latter being more obvious with the aggravation of neurological symptoms in DFD patients.

Keywords: type 2 diabetes mellitus, diabetic peripheral neuropathy, diabetic foot disease, sarcopenia, correlation

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Continued here:
Correlation Between Diabetic Peripheral Neuropathy and Sarcopenia in P | DMSO - Dove Medical Press

Diabetic Neuropathy: High sugar ranges in blood can result in many ailments. One of its severe results is nerve injury ( Nerve injury ) is. In medical phrases its known as diabetic neuropathy ( Diabetic Neuropathy ) is known as. Diabetic neuropathy strikes the nerves of your toes and legs.

->But it might probably additionally have an effect on the fingers and arms. You might really feel ache and numbness. Sometimes, a tingling in your toes and toes can be an indication of this situation. It can have an effect on your digestive system, blood vessels, urinary tract in addition to your coronary heart. Therefore, it turns into essential to protect in opposition to it in time.

To keep away from nerve injury its essential to preserve blood sugar ranges beneath management. If its ignored for too lengthy, it might probably trigger incapacity. In very extreme circumstances, it is usually prone to trigger amputation of the limbs. The most harmful factor is that you could be not even know that youre experiencing nerve injury till its too late. This is as a result of the signs can generally be deceptive. Let us know how you can stop such sort of nerve injury in diabetes

Control your blood sugar stageControlling blood sugar ranges is the primary rule to forestall diabetic neuropathy. Keep your blood sugar ranges inside regular limits. If it fluctuates, discuss to your physician. He can change your medication. But, in your half, you must always monitor your blood sugar stage. You can simply do that at residence with a blood sugar meter. Also you should definitely go for the A1C take a look at each six months.

Take care of your toesYour toes are essential. It is essential to care for them. If nerve injury has already occurred, then you could be alert for any harm. This is as a result of you arent prone to really feel ache, your harm might trigger issues. Cut your nails commonly and pat your toes. Use lotion and apply it between your toes as effectively. Wash your toes with heat water and cleaning soap. Dry them effectively. Talk to your physician if you could put on any particular footwear for diabetic neuropathy. Even if it isnt obligatory, all the time put on comfy footwear.

Exercise safelyTalk about exercising in case of diabetes, then observe some guidelines. If you might be jogging or working, put on good high quality trainers. Some actions will not be good for you. Seek the recommendation of a educated skilled earlier than beginning any new train.

Read more:
This methodology reduces the danger of diabetes neuropathy in diabetes - Sahiwal Tv

DOYLESTOWN, Pa., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (KLFE) (Kannalife or the Company), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has completed its phase 1 study funded by a grant (1R41DA044898-01) from the National Institutes of Healths (NIH) National Institute on Drug Abuse (NIDA). The study was performed by Kannalife and the Lewis Katz School of Medicine at Temple University (LKSOM) to assess KLS-13019, the Companys patented cannabidiol (CBD)-like molecule as a potential treatment of neuropathic pain and drug dependence.

The pre-clinical grant study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative in the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN).

The animal model portion of the study was conducted by Sara Jane Ward, PhD, Assistant Professor of Pharmacology at LKSOM. Dr. Ward had independently begun the research focused on CBD for the potential treatment of CIPN in 2010 at LKSOM and published three papers on the subject prior to beginning the collaboration with Kannalife.

Im very excited about the results we have obtained with KLS-13019 to date. In our model, KLS-13019 is at least as effective as CBD to prevent neuropathic pain; however, KLS-13019 is also effective to reverse neuropathic pain as a consequence of cancer chemotherapy, whereas CBD was not effective under our test conditions. We will continue to explore the possibility that KLS-13019 could be even safer and more effective than CBD, stated Dr. Ward.

Kannalife performed pharmacology studies on the mechanism of action of KLS-13019 and its effects on the sodium-calcium exchanger (mNCX-1), an important regulator of mitochondrial function. Results of the studies performed by Douglas Brenneman, PhD, for Kannalife, have been published in the Journal of Molecular Neuroscience in a paper titled, Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity.

For KLS-13019 treatment of CIPN, significant progress has been made in identifying a molecular mechanism of protection from the complex effects of paclitaxel-induced damage of sensory nerve cells, stated Dr. Brenneman.

The completed study could lead to a Phase 2 grant and further advances Kannalifes belief that KLS-13019 could become a viable drug candidate, and an alternative to opioids, as a treatment for patients suffering from CIPN, and chronic pain management. CIPN is a disabling pain condition that afflicts between 30-40 percent of patients undergoing chemotherapy, for which there is no effective prevention strategy and treatment of established chronic CIPN is limited.1 Existing treatment options primarily include anticonvulsants and antidepressants, as well as opioids in more severe cases of CIPN.2

The global market for neuropathic pain was valued at more than $5 billion in 2015, and in 2016, CIPN accounted for more than 42 percent of market revenue. Its estimated that by 2024, the total global neuropathic pain market will be worth more than $8.3 billion.3-4

The global opioids drug market was valued at $22.85 billion in 2017 and is expected to reach $32.6 billion by 2026, at a CAGR of 4.54% during a forecast period. Opioids are mainly used in cancer pain management and end-stage diseases in which painkilling care is required. The rising prevalence of cancer, high demand for pain therapeutics in the treatment of chronic pain, regulatory approvals and launches of innovative drug formulations, and increasing approval rate of abuse-deterrent formulations of opioid drugs are major driving factors of the global opioids drugs market. Extensive misuse of opioids, the growing incidence of death related to opioid overdose, and the rising number of lawsuits against opioid manufacturers are hindering the growth of the market. 5

A recently released animated video from Kannalife describes a Mechanism of Action (MOA) for KLS-13019. This video can be accessed on the Companys website at http://www.kannalife.com and via Vimeo at https://vimeo.com/371214213.

Research reported in this press release was supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) in the amount of $299,916 under award number 1R41DA044898-01.

Story continues

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Temple HealthTemple University Health System (TUHS) is a $2.2 billion academic health system dedicated to providing access to quality patient care and supporting excellence in medical education and research. The Health System consists of Temple University Hospital (TUH); TUH-Episcopal Campus; TUH-Jeanes Campus; TUH-Northeastern Campus; The Hospital of Fox Chase Cancer Center and Affiliates, an NCI-designated comprehensive cancer center; Temple Transport Team, a ground and air-ambulance company; Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices; and Temple Faculty Practice Plan, Inc., TUHSs physician practice plan comprised of more than 500 full-time and part-time academic physicians in 20 clinical departments. TUHS is affiliated with the Lewis Katz School of Medicine at Temple University.

Temple Health refers to the health, education and research activities carried out by the affiliates of Temple University Health System (TUHS) and by the Katz School of Medicine. TUHS neither provides nor controls the provision of health care. All health care is provided by its member organizations or independent health care providers affiliated with TUHS member organizations. Each TUHS member organization is owned and operated pursuant to its governing documents.

It is the policy of Temple University Health System that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

About KLS-13019KLS-13019 is Kannalifes leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Companys family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

References

CONTACT:

Public Relations:

Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Mike Mulvihill, Senior Counsel of PadillaP: 804-334-2292E: mike.mulvihill@padillaco.com

Investor Relations:Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

See the rest here:
Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential...

Diabetic neuropathy is a complication that occurs due to prolonged excessive blood sugar level. It basically damages the nerves present in legs and hands. Depending on the nerves, diabetic neuropathy has affected, you feel the symptom ranging from pain and numbness in legs to digestive problems, and cardiovascular issues.

If you are suffering from diabetes and is not able to control the blood sugar level, the walls of your blood vessels may become weak and get damaged. Apart from diabetes, a combination of factors including smoking, drinking alcohol, genetics, and inflammation in nerves can cause nerve damage. In case of non-availability of timely treatment, the condition may aggravate and lead to various complications. Here, we tell you about them.

Also known as a neuropathic joint, Charcot joint is a progressive joint disorder that causes discomforting pain sensation. It causes joints to deteriorate that shows symptoms including swelling in joints, instability, and joint deformity.

If diabetic neuropathy damages the nerves controlling your bladder, you wont be able to empty it completely. This can lead to the accumulation of bacteria in the bladder and kidneys. This is what is called urinary tract infection. This can make you disable to control the muscles that release urine and feel urination. This can further lead to leakage and unwanted embarrassment.

In case diabetic neuropathy leads to the damage of the nerves controlling the functions of your digestive tract, you will experience constipation, diarrhoea or both. Nerve damage associated with diabetes has been found to cause a condition called gastroparesis in which your stomach either empties too fast or not at all. This can lead to an excessive increase in blood sugar level.

Nerve damage has been found to affect the functions of your sweat gland and thus makes it problematic to control body temperature. If you have autonomic neuropathy, you will experience too much sweating. Notably, too little or no sweating can be debilitating.

Continue reading here:
Suffering From Diabetic Neuropathy? Beware of These Complications - India.com

Flex Wheeler has gone through a considerable amount over the past several months. It appears that his leg amputation was only one of the hardships that the bodybuilding legend has been going through physically. Now it appears that Flex Wheeler has been afflicted with another ailment.

The veteran bodybuilder has apparently been dealing with neuropathy. But rather than let this nerve damage diagnosis get him down, Flex Wheeler is once again showing the heart and resolve of a champion.

If a leg amputation couldnt keep Flex Wheeler out of the gym then you can bet a little nerve damage isnt going to stop the legend. Here he is hitting the gym to work back like a true savage.

From what everything Flex Wheeler has been through, it appears that nothing can hold this IFBB legend back.

For more news and updates, follow Generation Iron on Facebook, Twitter, and Instagram.

Managing Editor at Generation Iron, Jonathan Salmon is a writer, martial arts instructor, and geek culture enthusiast. Check out his Instagram, Twitter, Facebook, and Sound Cloud for in-depth MMA analysis.

Header image courtesy of Instagram

View post:
Flex Wheeler Battles Through Nerve Damage, Hits the Gym to Train Back - generationiron.com

A multicentre study across 18 centres finds 10kHz safe and effective for the treatment of painful diabetic neuropathy. Sensory improvements were observed in many patients who underwent stimulation with these parameters, as well improvements in quality of life measures. Erika Petersen, University of Arkansas for Medical Sciences, Little Rock, USA, presented these data at the North American Neuromodulation Societys (NANS) annual meeting (2326 January, Las Vegas, USA) and told delegates that the study is due to run through 24 months, with later evaluations of health economics and pain medication usage.

Our clinical trial is the largest randomised controlled trial to date, involving 216 patients randomised 1:1 to conventional medical management [n=103] alone or conventional medical management plus high frequency 10kHz stimulation [n=113], explained Petersen.

She added that all patients were evaluated by independent medical monitors before they were enrolled in study, and were required to have at least 5 of 10cm of the visual analogue scale (VAS) as well as a BMI <45 to be included. When looking at the demographics of the two arms, Petersen said, they are identical; no significant differences were observed in terms of duration of diabetes, duration of time of painful diabetic neuropathy, gender, and other factors.

Lead location was T8T11. Petersen posited that this is the typical location for addressing lower limb and lower extremity pain. She further emphasised that one of the endpoints of the study was safety. For the stimulation group, 19 adverse events [occurred] in 15 patients, two of which were rated as a serious adverse event, she acknowledged, adding that one arose due to infection, while the other was acquired at plantation.

I want to highlight our infection rate, Petersen said. People worry about diabetics having a higher risk of infection. But, what we can see for this population, is a 1.8% rate, which is comparable to the majority of studies in the literature for this population.

For the primary endpoint analysis, Petersen and her co-investigators looked at a composite of safety and effectiveness, in terms of pain reduction at three months. Those with 50% pain relief without a worsening neurological deficit from baseline were characterised at responders. Of the patients receiving SCS stimulation, 86% were considered responders at three months, compared to only 5% of patients in the conventional medicine management arm, reported Petersen, adding that the team observed a trial stimulation success rate of 94%.

She alluded to the reduction in VAS scores, which decreased from 7.6 (lower limb VAS) at baseline to 2.4 at one month, and 1.7 at three months. I hope to be able to show you think maintained at 24 months when we present those data in the future, Petersen noted. Moreover, through looking at individual pain relief between the stimulator and the conventional management group, it was revealed that 77% of stimulation patients achieved pain relief, compared to only 5% of controls.

Part of the assessment was to have each investigator assess sensory changes within the patients, Petersen explained. The team had asked patients to draw out subjective diagrams of where they perceived numbness, both at baseline and three months. We were able to perceive what seemed to be a change in sensation in the stimulator population in 72% of those patients, Petersen confirmed.

But pain relief is nothing without improving quality of life, said Petersen, alluding to the fact that investigators examined three measures of sleep, each of which saw significant improvements. They also implemented a six-minute walking test as a means of achieving an objective measure of functional improvement. Compared to the conventional medical management group, the stimulator patients walked further in six minutes at the three-month time point. When you look at this by individuals, Petersen discussed, you can see that it is not across all patients, but the average and median change allows for a longer distance walked [of 39 metres; a 17% increase] in the same amount of time.

In terms of impression of change, both patients themselves as well as the clinicians evaluating them were asked to assess their improvement. In total, 67% of the stimulator population said they are better/a great deal better than baseline, compared to a mere 2% of controls. These findings were reflected throughout a multitude of other functional indicator questionnaires, noted Petersen.

Read the rest here:
News from NANS: 10kHz safe and effective for treating painful diabetic neuropathy, multicentre study finds - NeuroNews International

Waldenstrm macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma that mainly affects elderly patients. Complications of the disease are usually attributable to tumor load or the presence of monoclonal immunoglobulin M (IgM). With limited approved treatment options by the US Food and Drug Administration (FDA), the demand for new therapies is high.

In a review published in Blood, Meletios A Dimopoulos, MD, and Efstathios Kastritis, MD, of the department of clinical therapeutics at the University of Athens in Greece, summarized current literature surrounding the treatment of WM.1 They also reviewed several example cases using clinical data from their institution.

Diagnostic Workup and Indication for Therapy

If the presence of IgM is confirmed by immunofixation electrophoresis, and a bone marrow biopsy reveals infiltration with clonal lymphoplasmacytic cells, a diagnosis of WM is established. Indolent cases are defined as those with less than 10% clonal infiltrate, but there is no established threshold for the amount of clonal cell infiltrate required for diagnosis. Although variation in clonal morphology is high, established cell morphology and immunophenotypic criteria aid in differential diagnosis among other conditions that exhibit a similar phenotype.1

During the initial workup, ruling out other causes of presenting symptoms is important. At initial presentation, the most common symptoms are anemia and cytopenias (42%), B symptoms (25%), and hyperviscosity (17%). As a result, additional laboratory parameters should be measured, including iron studies, serum albumin, lactate dehydrogenase, and beta-2 microglobulin. The measurement of monoclonal IgM levels is also necessary, as hyperviscosity syndrome, a key marker of symptomatic disease, is related to elevated IgM levels; however, this relationship is not linear.1

Another common complication of the disease is peripheral neuropathy, which in many cases is the sole indication for treatment in asymptomatic patients. WM-associated neuropathy is often slowly progressing, sensory, and symmetrical in nature. Hence, rapidly progressing peripheral neuropathy may indicate an unrelated cause.

Because of a prolonged asymptomatic period, often exceeding 5 to 10 years, it is crucial to ensure patients have an indication for therapy. Though some clinical and laboratory indications have been proposed, clinical judgment is often necessary. Monoclonal IgM levels alone are insufficient to determine an indication for therapy. Currently, there are no data to help guide clinical decision making on whether to delay or commence therapy in asymptomatic patients. In these cases, enrollment into a clinical trial may be a suitable option.

Originally posted here:
Current and Prospective Treatment Options for Waldenstrm Macroglobulinemia - Hematology Advisor

Cancer has an impact on every part of a patient's life. At GBMC Healthcare, the fight against cancer is about more than treating the disease. Delia Chiaramonte, M.D., Medical Director of Integrative and Palliative Medicine at GBMC, is leading the charge on integrative cancer care.

"It's not just about treating the cancer. It's also about how the person is coping, what side effects they may have from the disease itself or from the treatment, and how those symptoms make their life harder to manage," she says. "Treating the whole person is a really important part of cancer care."

These symptoms can be caused by a variety of internal and external sources, and Dr. Chiaramonte says it's important to get to the root of the cause of the symptom to better treat the patient.

"We hear the patient's symptoms then make an evidence-supported treatment plan that's different for every person, based on what their symptom is and why we think their symptom is happening," she explains.

For example, one person may not be sleeping well because of a physical reaction to chemotherapy. Another may not be getting good sleep because their mind is filled with anxious thoughts about their diagnosis.

Dr. Chiaramonte says there are three main causes of symptoms, and the Integrative Medicine Program makes it easier for patients to get an evidence-based, effective treatment plan and to receive those treatments at the Sandra & Malcolm Berman Cancer Institute at GBMC.

"We pull out all the causes and then address them with the treatment that is likely to work on that particular person, and often it's not just one cause," she explains.

The mind-body connection

The sympathetic nervous system directs our body's "fight or flight" response, which can be caused by both external factors and our own thoughts.

"Because the mind and body are connected, our anxious thinking can generate the 'fight-or-flight' response, and that can result in all kinds of physical symptoms, including increased pain, palpitations, changes in GI function, sleep, and nausea," Dr. Chiaramonte says.

According to Dr. Chiaramonte, there are a variety of ways to help decrease the sympathetic nervous response system, including craniosacral therapy (a light-touch manual therapy technique that works to balance and facilitate healing in the body) and massage. These methods reduce patients' anxiety.

Cancer treatment symptoms

It's no secret that chemotherapy and radiation can be taxing on the body. Nausea, fatigue, and neuropathy (nerve pain caused by damaged nerves) are just some of the side effects of cancer treatments that integrative modalities can help alleviate.

"Some energy medicine has been shown to help chemo-induced peripheral neuropathy," Dr. Chiaramonte says. "Many people come in with fatigue, usually from a combination of poor sleep and treatments. Acupuncture, meditation and guided imagery, reiki (a stress reduction and relaxation technique involving a trained practitioner), and yoga have all been shown to help fatigue."

Physical pain

Dr. Chiaramonte reiterates that the Integrative Palliative Medicine Program is just that: an integrative medicine program and not an alternative to standardized cancer care.

"I treat pain with medicines, with different kinds of opiates and complementary medications," she says. "But acupuncture has been shown to decrease pain. Meditation and guided imagery have been shown to decrease pain. Reiki has been shown to decrease pain. Depending on the person, we may use multiple modalities to help them manage their pain."

Massage is also an oft-used modality for physical pain.

"Often, when something hurts in our body, the muscles around it contract and tighten to try to protect it, and over time it can become the actual contraction of the muscle that hurts, not necessarily the underlying factor," Dr. Chiaramonte says.

She explains this can also tie into the mind-body connection because "if you're generating a lot of anxious thinking, you're more likely to continue to have this muscle tension, and massage can help."

Integrative treatment plans will vary by patient, which Dr. Chiaramonte says is the key to taking care of the mind, body, and spirit of every individual.

"We find out the 'why' behind each patient's symptoms, pull out the causes, and then come up with a plan for that particular patient, using all the tools that work."

For more information Integrative Medicine at GBMC HealthCare, click here.

Read this article:
How integrative medicine is changing the way cancer is treated - Fox Baltimore

VertexMarketInsights.com has published an innovative statistics of the market titled as Neuropathy Pain Treatment Market. To clarify the various aspects, the analyst studies and elaborates the terms by using qualitative and quantitative research techniques. Finance teams can use a variety of corporate planning applications to fulfil the budgeting, planning & financial modelling, needs of their organization, whatever its size, industry and location.

Graphs, tables, bar graphs and pie charts have been represented in sophisticate manner for the clients to better understand the analysis. To enlarge the businesses, customers get increased rapidly through Neuropathy Pain Treatment industry techniques.

Download Exclusive Sample of Neuropathy Pain Treatment Markets Premium Report @ https://vertexmarketinsights.com/report/41823/world-neuropathy-pain-treatment-market-research-report-2024-covering-usa-europe-china-japan-india-and-etc/ #request-sample

Leading Establishments (Key Companies):PfizerDepomedEndoGrnenthal GroupArbor PharmaceuticalsEli Lilly

Different regions, such as Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East & Africa, Egypt, South Africa, Israel, Turkey and GCC Countries are focused to give the summarized data about the production of Neuropathy Pain Treatment market.

The global Neuropathy Pain Treatment Market is served as a backbone for the enlargement of the enterprises. To address the challenges, the report examines different key factors such as drivers and opportunities. Restraints are considered for evaluation of risk in market.

Segments covered in the report

This report forecasts revenue growth at a global, regional & country level, and analyses the market trends in each of the sub-segments from 2015 to 2025. For the purpose of this study, VertexMarketInsights have segmented the Neuropathy Pain Treatment market on the basis of type, end-user and region:

Type Outlook (Revenue in Million USD; 20152025):Calcium channel alpha 2-delta ligandsSerotonin-norepinephrine reuptake inhibitors

End Use Outlook (Revenue in Million USD; 20152025):Retail PharmaciesHospitals

Neuropathy Pain Treatment Market Summary: This report includes the estimation of market size for value (million US$) and volume. Estimation methodology validate the market size of Neuropathy Pain Treatment industry, to estimate the size of various other dependent submarkets in the overall market. Secondary research is used to identify the top players in the market, and their market shares have been determined through primary and secondary research. Each type is studied based on classification as Sales, Neuropathy Pain Treatment Market Share (%), Revenue (Million USD), Price and Gross Margin.

If You Have Any Query, Ask Our Experts @ https://vertexmarketinsights.com/report/41823/world-neuropathy-pain-treatment-market-research-report-2024-covering-usa-europe-china-japan-india-and-etc/ #inquiry-before-buying

Report Objectives:

Target Audience:

Table of Content:

Global Neuropathy Pain Treatment Market Research Report 2020-2025

Chapter 1: Industry Overview

Chapter 2: Neuropathy Pain Treatment Market International and China Market Analysis

Chapter 3: Environment Analysis of Market.

Chapter 4: Analysis of Revenue by Classifications

Chapter 5: Analysis of Revenue by Regions and Applications

Chapter 6: Analysis of Neuropathy Pain Treatment Market Revenue Market Status.

Chapter 7: Analysis of Industry Key Manufacturers

Chapter 8: Conclusion of the Neuropathy Pain Treatment Market Industry 2025 Market Research Report.

Continued to TOC

For more detailed Pdf Copy of Table of Content Describing Current Value and Volume of the Market with All Other Essential Information click @ https://vertexmarketinsights.com/report/41823/world-neuropathy-pain-treatment-market-research-report-2024-covering-usa-europe-china-japan-india-and-etc/ #table-of-contents

****Thanks for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest. ***

Tags: Global Neuropathy Pain Treatment IndustryGlobal Neuropathy Pain Treatment MarketGlobal Neuropathy Pain Treatment Market growthGlobal Neuropathy Pain Treatment Market ShareNeuropathy Pain Treatment

View original post here:
Neuropathy Pain Treatment Market 2020 Industry Sahre, Growth, Top Manufacturers, Globally Development and Forecast to 2025 - TechNews.mobi

After facing months of rehab due to injury, pole vaulters Arielle Sclar 22 and Lulu Knowles 21 recently returned to the track and field team with the support of their teammates, coaching staff, and the sports medicine department.

In the winter of my senior year of high school I was at a pole vault meet, and I landed poorly and tore my ACL and meniscus, Sclar said. I waited the full year to come back which is protocol for ACL surgery, and then there were complications, and I had a second surgery at the start of [the] fall [2019] semester.

Sclar said that it was difficult getting back into pole vaulting after her knee injury since she was not able to do any cardio exercises during rehab. She described her recovery process as long and intensive, but noted the consistent support from her teammates.

Ive never felt disconnected from the team, she said, despite being out for most of last season.

Knowles was injured at the end of her freshman year. Her injuries led her to switch from triple jump to pole vault.

I shattered my kneecap when I was still a triple jumper, she said. I really wanted to be part of the team, and since I was a gymnast, my coach asked if I would pole vault. Sophomore year I had ulnar neuropathy, which I trained and competed through for a while, but then it got really dangerous and I had to get surgery. Ulnar neuropathy, according to Medical News Today, affects the nerve the runs along the arm along the elbow and into the fingers on the outside of the hand.

Track and field head coach Michele Curcio witnessed their recovery and said that they really embraced their rehab.

Sports medicine did a great job of making sure they were ready, Curcio said. Sometimes the student athlete gets ahead of themselves. As an athlete, you think youre going to be able to do things quicker than the normal person.

Both athletes added that not being able to physically participate on the team was challenging at times.

Sometimes its really frustrating watching people do the sport you love when you cannot take part in it, Knowles said. I had contemplated just quitting, I had so many injuries. But sitting out made me realize how much I loved being part of a team and competing. Pole vault definitely gives me that thrill that I love and being out made me love the sport even more.

Its not a great feeling watching everyone else be healthy and doing what you wish you could be doing, Sclar added. But it was easier for me when thinking of how exciting it would be to be back.

While Knowles suffered her injury in a different field event, returning to the same exercise that initially caused the injury, as was the case with Sclar, presented an additional obstacle to their recovery.

The hardest thing is to come back [and] to do that thing that made you hurt, Curcio said. You have to bring them back slowly and break that mental barrier.

The support and positive energy of their teammates played a big role in their recovery and mental toughness.

Every team member here appreciates each other and being on the team, and a lot of them have gone through the same things, so I think that type of support before and after [an injury] is important, Curcio said.

Both Knowles and Sclar are now back with the team and competed last weekend at the DeSchriver Invitational. Knowles and Sclar placed fifth and sixth, respectively, in the pole vault with marks of 2.90 and 2.75 meters. Being back with the team full-time is already having an impact on both women.

People dont recognize how many things go on to make the whole track team be functional and do well, Sclar said. Everyones coming from a very different place to make a common goal as a team unit.

I love our team dynamic, especially this year because we have some freshman who joined and brought great positive energy, Knowles added. Everyone has a different major and a different story, you just get to talk to so many different people.

Knowles, Sclar and the rest of the track and field team return to action today at the University of Albany winter classic in Staten Island, N.Y.

Read the original:
On the track to recovery: Pole vaulters talk about their returns from injuries - The Lafayette

DOYLESTOWN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (KLFE), a biopharmaceutical company specializing in the research and development of cannabinoid therapeutics, announced today that it has issued a letter to its shareholders providing commentary on the Companys recent initiatives and corporate updates.

The Companys Chief Executive Officer, Dean Petkanas, commented: 2019 was a milestone year for Kannalife. Its nice to see dedicated shareholders, management, employees and trusted partners and collaborators bring a small enterprising 10-year-old startup company to the cusp of expansion and commercialization efforts in 2020. With limited resources over the past decade, we have been truly blessed as we have built an impressive track record in the cannabinoid therapeutics space. We can now share the potential of our science with investors as a publicly traded company. We hope our existing and future shareholders will join us in our excitement as Kannalife continues to execute on innovative new technologies in the biotech and pharmaceutical arena.

Highlights of the letter include:

To read the Letter to Shareholders in full, please visit: https://www.kannalife.com/wp-content/uploads/2020/01/Kannalife-Inc.-Shareholder-Letter-200128.pdf.

About KLS-13019KLS-13019 is Kannalifes leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the companys business plan, plan of operations, the viability of the companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

CONTACT:

Public Relations:

Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Mike Mulvihill, Senior Counsel, PadillaP: 804-334-2292E: mike.mulvihill@padillaco.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

View original post here:
Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead - Yahoo Finance

TULSA, Okla. Cancer treatment is more than surgery, radiation and chemotherapy.

Physical and occupational therapy are also important tools in a patient's fight for a normal life.

Merideth Metz used customized therapy to recover from the side effects that can occur with treatment.

When a doctor told Metz to give up after her colon cancer diagnosis, she left and went to Cancer Treatment Centers of America in Tulsa about a year and a half ago.

"No active cancer as of last September, confirmed in October, and now, I'm here for my first three month check," Metz said.

Once her chemotherapy was done, she needed physical therapy, speech therapy and occupational therapy to help with neuropathy that's common after chemo.

"Our job is to focus on the patient's wants," said Barry Calvert, an occupational therapist with CTCA. "Trying to help them stay actively participating in those as best they can throughout the course of their treatment."

Calvert came up with a creative option, like art to document her journey towards healing.

Now, Metz is looking forward to her next effort in the new year.

To learn more about Cancer Treatment Centers of America, click here.

Stay in touch with us anytime, anywhere.

Download our free app for Apple and Android and Kindle devices.

Sign up for newsletters emailed to your inbox. Select from these options: Breaking News, Severe Weather, School Closings, Daily Headlines and Daily Forecasts.

Follow us on Twitter

Like us on Facebook

Originally posted here:
Health News 2 Use: Customized therapy helps patients recover - kjrh.com

MONTROSE TWP, MI The 83-year-old man who died following a fire at a Montrose Township home is being remembered by family as kind.

Firefighters were called out around 6:50 p.m. Jan. 24, to a blaze at the Riverside Mobile Home Park located at the corner of Virginia and Joan drives.

A man inside the home died in the fire. He has been identified by family as Ellis Paul Kuykendall, 83.

Man found dead at scene of Montrose mobile home fire

Lisette McKiernan, Kuykendalls granddaughter, said he was originally from Tennessee but grew up in Las Vegas.

McKiernan took care of Kuykendall for the last decade prior to him moving in with her son Matthew Price several months ago.

Theyd lived in the mobile home park for approximately three weeks before the fire.

Kuykendall was a U.S. Air Force veteran, serving two years of active duty.

He was just a very witty man, said McKiernan. He had a good sense of humor. He was just a very kind individual."

Kuykendall enjoyed playing word searches and rummy. McKiernan kidded that his nurses had to learn the game in order to get in some games.

Hed been diagnosed with neuropathy in his legs that left him wheelchair-bound, McKiernan said.

No other injuries took place in the fire, but McKiernan said her son and two grandchildren -- a 4-year-old boy and a 6-year-old girl -- lost their home.

Were just pretty much devastated right now, she said.

Community members have reached out to Price with donations.

Thank you to the community for reaching out and all their support, said McKiernan. Matthew appreciates everything the community has provided for them.

A GoFundMe page has been set up to help the family transport Kuykendall back to Las Vegas and help Price get back on his feet.

The cause of the fire remains under investigation.

See the article here:
Veteran who died after Montrose-area fire remembered as witty, kind - MLive.com

Abstract / Synopsis:

Gene therapy for Leber's hereditary optic neuropathy appears highly promising for increasing the best-corrected visual acuity in this patient population.

This article was reviewed by Jiajia Yuan, PhD

Gene therapy for Lebers hereditary optic neuropathy (LHON) seems to be the first promising treatment for the disease.

LHON, a maternally inherited disease, causes optic nerve atrophy that in most cases results in simultaneous or sequential bilateral visual loss. Disease onset typically happens in patients between 14 to 21 years of age.

The most frequently occurring offending mutation is ND4 that appears in about 90% of Chinese patients and in about 50% to 60% of U.S. patients, according to Jiajia Yuan, PhD, Tongjl Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

No treatment is currently available for this disease.

Related:Gene therapy offering hope for retinal, corneal patients

LHON treatmentDr. Yuan and colleagues initially treated nine patients with LHON with gene therapy in 2011. With this first attempt, she reported seven of the nine patients had a significant improvement of 0.3 logarithm of the minimum angle of resolution (logMAR) VA at 36 months in the best-corrected visual acuity (BCVA).

We saw a durable response in six of these patients out to 75 to 90 months after treatment, she said. In addition, a bilateral improvement was achieved, as also was observed by other groups investigating gene therapy.

Gene therapy trialThese promising results prompted a second multicenter gene therapy trial that began in 2017 that include 149 Chinese patients and 10 Argentinian patients.

According to Dr. Yuan, the patients, who ranged in age from 7 to 45 years, received a fixed dose of 1 x 1010 mg/eye for all patients, regardless of age, Dr. Yuan explained.

Related: Research targets precision data for gene, cell therapy

Promising resultsThe treatment was found to be well tolerated and no severe adverse effects occurred, she said.

Keratitis developed in one eye at one month and anterior inflammation in one eye at three months that were both considered to be unrelated to the treatment.

Ocular hypertension was the most common adverse event that developed in 27.04% of eyes that decreased slowly over time after cessation of the steroid.

A significant improvement in the BCVA occurred in 63.21% (67 of 106 patients) at 12 months. The rest of the patients had not reached the 12-month time point at the time of this report. Similar to the initial study, the patients showed bilateral improvement.

This is a real-world study, in that there was no specific patient selection, Dr. Yuan explained. The patients ages spanned a wide range as did the time of disease onset and the pretreatment BCVA.

An evaluation of only the Argentinian patients showed that all had improvement in the BCVA.

These patients fared better overall than the other patients in the group, with the average improvement in the treated eye was 0.6 logMAR and the average improvement in the untreated eye was 0.9 logMAR, Dr. Yuan pointed out.

Related: Gene therapy for LHON: Deciphering phase III data

Importantly, this improvement in the BCVA is highly relevant for the ability of patients to function well during everyday tasks.

And the researchers saw results with the patients that were treated.

Dr. Yuan related that three months after treatment, a patient was able to cook and watch sporting events on the computer.

Dr. Yuan noted that gene therapy is a promising approach for patients with LHON.

Nine patients were treated in 2011 to 2012 and we continue to follow them, she concluded. This is the longest term data from human gene therapy to date.

Related: Gene therapy focus of Schepens lectures at AAO 2019

ConclusionsAccording to Dr. Yuan, nearly two-third of 106 patients who reached the 12-month follow-up point achieved a clinically significant improvement in the BCVA.

Importantly, no serious adverse events occurred in the real-world studies, she said. We are very excited about the potential impact of gene therapy on this disease.

Read more by Lynda Charters

Jiajia Yuan, PhDE: [emailprotected]This article is based on Dr. Yuan's presentation at the American Academy of Ophthalmology's 2019 annual meeting. Dr. Yuan has no financial interest in any aspect of this report.

Read the rest here:
Gene therapy zeroes in as LHON treatment - Ophthalmology Times

Global Medical Foods Market: Overview

One of the key factors boosting the growth of the global medical foods market is the rising awareness among the people regarding medical foods. The rising focus of the regulatory bodies on the manufacturing and labelling of medical foods will also be a key factor fuelling the growth of the medical foods market. In addition to this, the high focus by manufacturers on developing disease-specific formulas effective patients nutrition or diet care are also anticipated to result in the growth of the global medical foods market.

The report also enlists various factors which are anticipated to pose a challenge for the growth of the market. The current trends in the market and those that are anticipated to shape the future of the market have been discussed in detail in the report.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2558

By product, the medical food market is segmented into powder, pill, and others. Of these the powder segment has held a key share in the market as many medical food products are manufactured in powdered form and consumed in a semi solid or liquid form. By application, the global medical foods market is segmented into depression, diabetic neuropathy, ADHD, Alzheimers disease, and nutritional deficiency. Of these, diabetic neuropathy has been accounting for key shares within the market. The risk of neuropathy is boosted with age, diet changes, and unhealthy lifestyle.

In the years to come, it is anticipated that the nutritional deficiencies segment will develop a strong CAGR, as patients being treated for ADHD, autoimmune diseases, and cancer are likely to have high nutritional requirements, which is subsequently anticipated to boost the demand for medical foods.

Global Medical Foods Market: Snapshot

The global medical foods market has become increasingly important in the healthcare sector in recent years due to the rising awareness about its importance in complementing the treatment. Medical food comprises diets designed specifically to overcome the nutritional deficiencies caused by some diseases or to fulfill the specific dietary needs in the management of some diseases. The global medical foods market is likely to receive steady support from the healthcare sector in the coming years due to the rising prevalence of diseases such as Alzheimers among the elderly and ADHD among children, as these diseases are among the prime diseases that necessitate specific diet plans.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2558

Global Medical Foods Market: Key Trends

The rising geriatric population is a major driver for the global medical foods market. Old people are more likely to develop nutritional disorders as well as to fall prey to other diseases that affect their ability to absorb nutrients from their diet. Nutrition deficiency disorders are also more common among the geriatric demographic than in other patient classes, leading to the geriatric population becoming a key consumer segment for the global medical foods market.

The increasing prevalence of diabetes across the world is another key driver for the global medical foods market. Diabetic neuropathy is the leading application of the global medical foods market and is likely to retain dominance in the coming years. Diabetic neuropathy is becoming common among diabetic patients due to their often unhealthy lifestyles, with close to three-quarters of all diabetes likely to also suffer from some form of neuropathy. This is a key driver for the global medical food market, as the rising prevalence of diabetes in emerging regions has, in conjunction with the rising investment in the healthcare sector, created a conducive environment for growth of the market.

The rising prevalence of ADHD among children is also likely to remain a key driver for the global medical foods market. The growing prevalence of the disease has led to intensive research into its causation and treatment. The role of nutrition in the management of psychological problems such as ADHD has thus come under the scanner. On the opposite end of the spectrum, the rising prevalence of neurodegenerative conditions among the geriatric population is also likely to remain a key driver for the global medical foods market in the coming years.

Global Medical Foods Market: Market Potential

The global medical foods market is likely to witness a steady shift towards pills and away from powders. While powders can be easily mixed with various types of food, many patients dont enjoy their taste. This has led to pills becoming a preferred mode of delivery for many, and are thus likely to rise in demand in the global medical foods market in the coming years.

Apart from leading diseases such as diabetic neuropathy and Alzheimers, other diseases such as phenylketonuria (PKU) are also likely to come under the ambit of the medical food market in the coming years. In April 2017, PKU Sphere, a new medical food for patients of PKU was launched. PKU Sphere is claimed to contain a balanced mix of amino acids and glycomacropeptide, a protein essential for patients of PKU, who cant digest phenylalanine and have to fulfill their protein requirements in alternate ways.

Global Medical Foods Market: Geographical Dynamics

North America is likely to remain the leading regional contributor to the global medical foods market in the coming years due to the ready availability of advanced healthcare technology and a solid database regarding the dietary needs of patients suffering from various diseases. The rising prevalence of diabetes in North America, due primarily to the unhealthy lifestyle practiced by citizens in developed countries such as the U.S., is also likely to be crucial for the medical foods market in North America in the coming years.

Global Medical Foods Market: Competitive Dynamics

The leading players in the global medical foods market include Abbott, Fresenius Kabi AG, Targeted Medical Pharma Inc., Danone, and Primus Pharmaceuticals Inc. The steady support to development of sophisticated disease-specific formulas is likely to benefit the medical foods market in the coming years.

Read Comprehensive Overview of Report @https://www.tmrresearch.com/medical-foods-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Read the rest here:
Medical Foods Market Scope, Segmented By Company, Application and Region, Forecast To 2025 - Science of Change